About the Authors
- Daniel Rüdiger
-
Contributed equally to this work with: Daniel Rüdiger, Lars Pelz
Roles Conceptualization, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing
* E-mail: ruedigerd@mpi-magdeburg.mpg.de (DR); kupke@mpi-magdeburg.mpg.de (SYK)
Affiliation Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany
- Lars Pelz
-
Contributed equally to this work with: Daniel Rüdiger, Lars Pelz
Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing
Affiliation Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany
- Marc D. Hein
-
Roles Data curation, Formal analysis, Investigation, Methodology, Writing – review & editing
Affiliation Chair of Bioprocess Engineering, Institute of Process Engineering, Faculty of Process & Systems Engineering, Otto-von-Guericke University, Magdeburg, Germany
- Sascha Y. Kupke
-
Roles Conceptualization, Methodology, Project administration, Supervision, Validation, Writing – original draft, Writing – review & editing
* E-mail: ruedigerd@mpi-magdeburg.mpg.de (DR); kupke@mpi-magdeburg.mpg.de (SYK)
Affiliation Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany
- Udo Reichl
-
Roles Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing
Affiliations Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany, Chair of Bioprocess Engineering, Institute of Process Engineering, Faculty of Process & Systems Engineering, Otto-von-Guericke University, Magdeburg, Germany
Competing Interests
I have read the journal’s policy and the authors of this manuscript have the following competing interests: A patent for the use of OP7 (a DIP containing point mutations instead of a deletion in viral genome segment 7) as an antiviral agent for treatment of IAV infection is pending. Patent holders are S.Y.K. and U.R. Another patent for the use of DI244 and OP7 as an antiviral agent for treatment of coronavirus infection is pending. Patent holders are S.Y.K., U.R. and M.D.H. The remaining authors declare no conflict of interest.